Sector News

Gilead investing £19.6 million into UK expansion

February 10, 2015
Life sciences
Gilead Sciences is to create new UK commercial headquarters in London and expand its existing operations in the country.
 
The US biotech major is setting up home in Holborn and expanding its international operations in Uxbridge and UK R&D headquarters in Cambridge. The moves represent an increased investment of $19.6 million, doubling Gilead’s UK workforce to 600 by the end of the year – 400 will be based in London.
 
Boston-based Gilead’s investment was announced by Mayor of London Boris Johnson on US trade mission to drum up new business for the capital. The announcement comes less than a year since he launched MedCity, which aims to help the life sciences industry in London and the greater south east of England.
 
Mayor Johnson also announced that another Boston-based company Mobiquity, which specialises in mobile health, is investing £13 million over the next two years in a new London base. He said that Gilead and Mobiquity’s moves to London “further underline the growing importance of the life sciences industry in the UK as we look to ensure that this crucial sector becomes a key contributor to the capital’s growth and health”.
 
In November, Merck & Co announced a £42 million investment to create a new London licensing hub, expand research in Hertfordshire and fund clinical research in oncology and dementia. Pfizer is setting up a new gene therapy unit in the capital focused on rare diseases.
 
By Kevin Grogan
 

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend